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Abstract
Background: Body mass index (BMI), resting energy expenditure (REE) and fasting blood glucose (FBG) are major
preoperative assessments of patients’ nutrition and metabolic state. The relations and effects of these indices on
esophageal cancer patients’ postoperative short-term and long-term outcomes remain controversial and unclear.
We aimed to study the impact of BMI, REE and FBG in esophageal cancer patients undergoing esophagectomy.
Methods: Three hundred and six esophageal cancer patients who underwent esophagectomy were observed
retrospectively. Clinical characteristics, postoperative complications and survival analysis were compared among
different BMI, REE and FBG groups.
Results: There were significant linear relationships between REE, BMI and FBG indices, patients with low BMI
tended to have low REE (p < 0.001) and low FBG (p = 0.003). No significant difference was found in case of mortality
and postoperative complications among different groups. Low BMI (X2 = 6.141, p = 0.046), REE (X2 = 6.630, p = 0.010)
and FBG (X2 = 5.379, p = 0.020) were related to poor survival. FBG ≤90 mg/dL was independently associated with
poor survival (HR = 0.695; 95 % CI 0.489–0.987, p = 0.042). BMI and REE came to be stronger prognostic factors on
lymph node-negative patients and proved to be independent prognostic indicators (HR = 0.540; 95 % CI 0.304–0.
959, p = 0.035 and HR = 0.457; 95 % CI 0.216–0.967, p = 0.041, respectively).
Conclusions: BMI, REE and FBG are important prognostic factors in patients with esophageal cancer undergoing
esophagectomy and preoperative evaluation of these indices help to determine the prognosis in these patients.
Keywords: Esophageal cancer, Body mass index, Resting energy expenditure, Fasting blood glucose, Prognosis
Background
Esophageal cancer (EC) is the eighth most common can-
cer and the sixth leading cause of cancer mortality
worldwide [1]. Esophageal adencarcinoma (EAC) and
esophageal squamous cell carcinoma (ESCC) are the
most frequent histological subtypes. ESCC is the domin-
ant histological subtype in china [2]. The potential prog-
nostic indicators of esophageal cancer include histological
variants (histological grading, differentiation, invasion
depth and classification of lymph node metastasis) and
nutrition or inflammation based prognostic factors (total
lymphocyte counts, neutrophil to lymphocyte ratio (NLR),
serum albumin and so on). BMI, REE and FBG, which are
widely used to assess preoperative nutritional and meta-
bolic status, have also been described to be prognostic
predictors in several tumors [3].
Previous studies reported that high BMI was associ-
ated with increased risk of EAC while low BMI with
ESCC [4]. High BMI in surgical patients is thought to be
associated with increased comorbidities and postopera-
tive complications, but the influence of high BMI on
survival in patients undergoing esophagectomy is con-
troversial. Hayashi found patients with high BMI showed
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better overall survival (OS) and disease-free survival
(DFS) because of the early clinical diagnosis [5]. In con-
trast to this, Yoon pointed out that high BMI was inde-
pendently associated with two-fold worsening of DFS,
and OS after surgery for EAC [6]. Blom concluded that
BMI had no prognostic value on short-term and long-
term outcomes [7]. Compared with the previous studies,
the mean BMI in Western populations was higher and
had a greater incidence rate of EAC whereas the mean
BMI in Chinese population was found to be lower with
predominant ESCC. The effect of low BMI on postoper-
ative complications and long-term survival remains un-
clear. So our study assessed the relationship between
BMI and postoperative complications and long-term
survival in Chinese population.
Disorder of energy metabolism is a common
phenomenon in cancer patients. The energy metabolic
status among different cancers may not be the same.
Many researchers assessed the resting energy expend-
iture on cancer patients and no unanimous conclu-
sions have been drawn. In this study, patients’
preoperative REE was an estimated variable, and cal-
culated by the Mifflin-St. Jeor equation [8]. REE is the
sum of the metabolic activities of internal body and
can reflect patient’s physiques and muscle volumes,
and REE per kg total body weight (REE/kg) may reflect
the diffusion and metabolic rate of muscle more
accurately. So both REE and REE/kg were used to ex-
plore its effects on short-term and long-term out-
comes on esophageal cancer patients.
Epidemiologic evidence suggests that elevated blood
glucose is associated with many forms of cancer [9].
However, opinions toward the association between ele-
vated blood glucose and outcomes are mixed. Elevated
blood glucose may promote cancer progression and lead
to poor outcomes via pathways mediated high levels of
insulin and insulin-like growth factor [10]. On the other
hand, some studies proposed that diabetes-related
microvessel changes might play a protective role against
“neoplastic” cell metastasis in cancer patients and en-
hance cancer prognosis [11]. For EC, the relationship be-
tween the circulating glucose levels and prognosis has
never been reported. To examine effects of fasting glu-
cose levels at time of cancer diagnosis on postoperative
outcomes is another aim of this study.
So the purpose of the study is to investigate the prog-
nostic value using combined assessment of BMI, REE
and FBG in esophageal cancer patients.
Methods
Patients
Patients who underwent esophagectomy and lymph
node dissections during Sep 1, 2003 to Dec 31, 2008
were observed. Twenty-three patients who had palliative
or R1/R2 resections were excluded. Patients who had
histology other than SCC or AC (one lymphoma, one
melanoma, one neuroendocrine carcinoma, one stromal
tumor and two small cell carcinoma) were excluded. Pa-
tients who received neoadjuvant therapy were also ex-
cluded. Three hundred and six patients with histologic
documentation of AC or SCC were included. All pa-
tients provided written consent and this retrospective
study was approved by the Institutional Review Board of
Huashan Hospital, Fudan University.
Clinical data
Preoperative staging was performed in all patients by
means of barium meal test, fibro-gastroscopy, computed
tomography of the chest and abdomen and ultrasound
of the neck and retroperitoneal lymph nodes. Some
patients also received whole body positron emission
tomography (PET)-CT scanning. All patients were
assessed for physiological ability to undergo esophagec-
tomy. These evaluations included pulmonary function
test, cardiac function test and nutritional assessment.
One hundred and eighty-six patients with tumors in
middle or lower thoracic esophagus and no evidence of
lymph node involvement in the superior mediastinum or
neck region received transthoracic esophagectomy via
left thoracotomy which also included a two-field lymph-
adenectomy; 53 patients with tumors in the middle or
upper thoracic esophagus and possible lymph node me-
tastasis in the superior mediastinum or neck region re-
ceived McKeown 3-hole esophagectomy with three-field
lymphadenectomy; 67 patients with tumors in the eso-
phagogastric junction received esophagogastrectomy
through median laparotomy.
TNM staging was performed according to the AJCC
7th edition guidelines. Patients were followed up every
6 months for the first 3 years and then annually. Survival
time was measured as the time from the date of surgery
to the date of death or the latest follow-up time.
Endoscopy, CT, PET-CT and Radionuclide bone scan
were performed if recurrent or metastatic disease was
suspected.
Patients’ weight and height were measured at their
first hospitalization. BMI was calculated as weight in ki-
lograms divided by height in meters squared.
REE was calculated by Mifflin-St. Jeor equation. The
applied technique to calculate BMI is as follows: for
males = 10 * weight (kg) + 6.25 * height (cm) - 5 * age
(y) + 5; for females = 10 * weight (kg) + 6.25 * height
(cm) - 5 * age (y) - 161. Both REE and REE/kg were
calculated.
The serum FBG concentration of patients was mea-
sured in the morning during the first hospitalization by
hexokinase method after fasting for 10 h. Serum albu-
min was measured by means of the bromocresol purple
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method using automated equipments, and all patients
were screened and excluded from acute and chronic
liver disease. The complete blood count test (leukocyte,
neutrophil, lymphocyte, monocyte, eosinophil, basophil,
platelet counts, and hemoglobin) was carried out by an
automated haematology analyser within one week prior
to surgery. NLR was calculated as the ratio of neutro-
phils to lymphocytes in peripheral blood. These reagents
and equipments were convenience-validated and stan-
dardized in our central clinical laboratory.
The 6-month preoperative weight loss was also mea-
sured and patients were divided into three categories:
No/Little (loss of 0 to 5 % body weight), Middle (loss of
5 to 10 % body weight) and Large (loss more than 10 %
body weight).
During the first few days after surgery, patients were
treated with total parenteral nutrition. An initial dose of
5–10 kcal.day−1.kg−1 of enteral nutrition was supplied
via a duodenum or jejunum feeding tube from the 2nd
or 3rd postoperative day and gradually increased to the
full dose of 25–30 kcal.day−1.kg−1. Some patients with
low BMI or low serum albumin levels were treated with
full dose of enteral nutrition from one week before sur-
gery to the tenth day after surgery.
Statistical analysis
All statistical analysis was performed with SPSS 16.0.
Spearman rank order correlation coefficient (Spearman’s
rho) for nonparametric data was used. Univariate ana-
lysis of survival was performed using Kaplan-Meier
method and log-rank test to estimate the prognostic
value. Multivariate analysis of survival was performed
using Cox-regression model to estimate hazard ratios
(HRs) with 95 % confidence intervals (CI) and identify
independent prognostic factors. The level of significance
was set to p < 0.05.
Results
Patient characteristics
The clinical characteristics and 5-years survival rate are
summarized in Table 1. The median follow-up time was
37 months. The overall 1-, 3- and 5-year survival rate
was 86.6, 60.8 and 47.1 % respectively.
The BMI distribution was as follows: low (<20 kg/m2),
n = 81 (26.5 %); normal (20–25 kg/m2), n = 186 (60.8 %)
and high (>25 kg/m2), n = 39 (12.7 %). The median REE
was 1387.5 kcal day−1 for male and 1064.0 kcal day−1 for
female where we defined the median REE as the cutoff
point and stratified patients into low REE group (male <
1387.5 and female <1064.0), n = 154 (50.3 %) and high
REE group (male ≥1387.5 and female ≥1064.0), n = 152
(49.7 %). The median REE/kg was 21.49 kcal.day−1.kg−1.
Compared with 245 (80.1 %) patients with REE/kg <
23.2, 61 (19.9 %) patients with REE/kg ≥23.2 had
significant worse survival, so 23.2 kcal.day−1.kg−1 was set
as the cutoff point. We divided the patients into two
groups according to serum FBG concentration where
108 patients (35.3 %) with low FBG (≤90 mg/dL) and
198 patients (64.7 %) with high FBG (>90 mg/dL).
Patient characteristics by BMI, REE, REE/kg and FBG
As shown in Table 2. Spearman’s rho indicated that pa-
tients with age > 65 years (p < 0.001) and advanced T-
stage (p = 0.040) were more likely to fall in the low REE
class. Smoking patients were more likely to be associated
with low BMI class (p = 0.013), low FBG class (p = 0.039)
but high REE/kg class (p = 0.001).
It was interesting to explore the relationship between
REE and REE/kg. Both high REE and low REE/kg pa-
tients were found to have better survival, which was
consistent with the spearman correlation analysis that
found patients with high REE tended to have lower REE/
kg (p < 0.001).
There were significant linear relations between BMI,
REE, and FBG, patients with low BMI tended to have
low REE (p < 0.001) and low FBG (p = 0.003). The trend
of a linear association between REE and FBG could also
be seen (p = 0.011).
There were close relations between REE/kg and
weight lost or BMI, patients with high REE/kg have
been found to lose more weight (p = 0.006) and have
lower BMI (p < 0.001).
Low FBG was more likely to be seen in patients with
high REE/kg (p = 0.025) and low albumin (p < 0.001).
Comorbidities, postoperative mortality and postoperative
complications
Preoperative comorbidities, mortality and postoperative
complications among different groups of BMI, REE,
REE/kg and FBG were presented in Table 2. COPD ap-
peared to be more frequent in low REE patients (p =
0.022), and diabetes was more common in high BMI pa-
tients (p = 0.006). All the seven patients with cardiovas-
cular disease belonged to low FBG class (p < 0.001).
Observing the short-term outcomes, no significant dif-
ference was found in postoperative mortality and major
postoperative complications among different BMI, REE,
REE/kg and FBG groups.
Nutrition or inflammation-based prognostic factors
Univariate analysis of nutrition or inflammation-based
prognostic factors found to be serum albumin (p <
0.001), but not Total lymphocyte counts (p = 0.780) or
NLR (p = 0.787), which was positively related to survival.
The spearman correlation analysis found higher serum
albumin levels were observed in high BMI, REE and
FBG but in low REE/kg groups.
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Univariate, multivariate and subgroup analysis
To evaluate the prognostic factors potentially related to
survival, univariate analysis was applied (Table 1) and
found no statistical associations of histologic subtype, sur-
gical type, weight loss and adjuvant chemoradiation with
OS. The prognostic factors were age, sex, differentiation,
T-stage, N-stage, BMI (X2 = 6.141, p = 0.046, Fig. 1),
albumin (X2 = 19.761, p < 0.001, Fig. 2), REE (X2 = 6.630,
p = 0.010), REE/kg (X2 = 5.063, p = 0.024, Fig. 3) and FBG
(X2 = 5.379, p = 0.020, Fig. 4). Patients with low BMI, REE,
FBG and high REE/kg had significant worse survival.
Variables significant (age, sex, differentiation, T-stage,
N-stage, albumin, BMI, REE, REE/kg and FBG) in Uni-
variate analysis were included in a multivariate analysis
(Table 3), which did not show a significant association
between BMI (HR = 0.945; 95 % CI 0.660–1.351, p =
0.755), REE (HR = 1.101; 95 % CI 0.718–1.688, p = 0.660)
or REE/kg (HR = 1.164; 95 % CI 0.717–1.890, p = 0.540)
and OS. Age, differentiation, T-stage, N-stage, albumin
(HR = 0.757; 95 % CI 0.589–0.973, p = 0.030) and FBG
(HR = 0.695; 95 % CI 0.489–0.987, p = 0.042) were inde-
pendent prognostic factors.
In order to assess the impact of BMI and REE on dif-
ferent tumor stages, we divided patients into subgroups
on the basis of N-stage (N0 vs. N1-4). Patients with
higher BMI and REE had significantly better OS in
subgroup of N0 (X2 = 15.507 p < 0.001 and X2 = 14.717,
p < 0.001, respectively), but no statistical significance in
subgroup of N1-4 (X2 = 1.952, P = 0.377 and X2 = 0.386,
p = 0.534, respectively). Multivariate analysis of sub-
groups revealed BMI (HR = 0.540; 95 % CI 0.304–0.959,
p = 0.035) and REE (HR = 0.457; 95 % CI 0.216–0.967,
p = 0.041) were independent prognostic factors for N0
patients but not for N1-4 patients.
Discussion
Our study identified that FBG level ≤90 mg/dL was in-
dependently associated with poor survival and also con-
firmed that advanced cancer stages remain the most
powerful prognostic factors. In addition, we observed
that BMI, REE and FBG were significant prognostic fac-
tors, but the prognostic value of BMI and REE is not the
same between different lymph node metastasis statuses.
For metastatic esophageal cancers, the most important
prognostic factors were FBG, albumin and cancer sta-
ging including differentiation and invasion depth




Age, year ≤65 210 53.3 0.003
>65 96 34.6
Sex Male 235 44.0 0.039
Female 71 57.8
Histology AC 98 49.7 0.590
SCC 208 45.7
Surgical type Transthoracic 186 47.0 0.701
McKeown 53 40.4
Transabdominal 67 51.2
Differentiation Well 38 61.9 0.000
Moderately 173 55.1
Poorly 95 24.9








TNM stage 0-I 42 80.5 0.000
II 118 66.5
III 146 21.3





Yes 78 41.7 0.187
No 228 48.8
Albumin <35 g/l 36 26.7 0.000
35–40 g/l 132 41.6
>40 g/l 138 57.8
Lymphocyte <1.1*109 42 48.7 0.780
1.1–3.2*109 228 47.5
>3.2*109 36 42.6
NLR <5 289 47.1 0.787
≥5 17 47.1
REE/kg <23.2 245 50.4 0.024
≥23.2 61 35.2
REE Low 154 40.4 0.010
High 152 55.3
FBG Low 108 35.0 0.020
High 198 51.7
Table 1 Patient characteristics and univariate analysis
(Continued)
BMI Low 81 36.8 0.046
Normal 186 49.1
High 39 62.8
CI confidence interval, OR odds ratio
The results were in bold, if the 95 % CI excluded 1 or p<0.05
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Table 2 Associations among characteristics, BMI, REE, REE/kg and FBG
Factors BMI, kg/m2 REE, kcal day−1 REE/kg, kcal day−1 FBG, mg/dL
<20 20–25 >25 p Low High p Low High p ≤90 >90 p
81 186 39 154 152 245 61 108 198
Age
≤ 65 50 134 26 0.332 87 123 0.000 157 53 0.001 73 137 0.774
> 65 31 52 13 67 29 88 8 35 61
Sex
Male 65 141 29 0.408 118 117 0.942 174 61 0.000 88 147 0.153
Female 16 45 10 36 35 71 0 20 51
Histology
SCC 54 132 22 0.561 103 105 0.682 165 43 0.639 81 127 0.052
AC 27 54 17 51 47 80 18 27 71
Differentiation
Well 7 28 3 0.869 19 19 0.507 31 7 0.552 14 24 0.557
Moderately 50 98 25 91 82 140 33 63 110
Poorly 24 60 11 44 51 74 21 31 64
T stage
Tis/T1 8 19 4 0.172 12 19 0.040 27 4 0.124 12 19 0.499
T2 14 42 9 30 35 54 11 22 43
T3 42 93 24 81 78 126 33 50 109
T4a 17 32 2 31 20 38 13 24 27
N stage
N0 36 98 22 0.241 73 83 0.476 131 25 0.262 54 102 0.551
N1 20 44 9 42 31 55 18 28 45
N2 20 27 5 26 26 38 14 22 30
N3-4 5 17 3 13 12 21 4 4 21
Bad habits
Smoking 51 86 17 77 77 0.909 112 42 0.001 63 91 0.039
Drinking 26 60 11 46 51 0.490 74 23 0.261 38 59 0.355
Comorbidities
Highblood 12 35 12 0.063 27 32 0.437 50 9 0.318 16 43 0.145
Copd 12 18 5 0.478 24 11 0.022 29 6 0.662 13 22 0.809
Cardiovascular disease 2 5 0 0.551 6 1 0.058 5 2 0.564 7 0 0.000
Arrhythmia 7 16 8 0.129 14 17 0.546 27 4 0.303 14 17 0.227
Diabetes 15 41 18 0.006 35 39 0.551 66 8 0.024 0 74 0.000
Mortality 1 5 1 0.970 6 1 0.058 6 1 0.706 3 4 0.673
Postoperative complications
Fistula 6 6 3 0.083 12 3 0.182 9 6 0.259 6 9 0.825
Sepsis 9 6 6 0.208 15 6 0.260 12 9 0.125 9 12 0.673
Pneumonia 7 11 8 0.615 16 10 0.892 20 6 0.676 8 18 0.233
Respiratory insufficiency 6 9 6 0.846 14 7 0.692 18 3 0.504 7 14 0.122
Arrhythmia 14 33 8 0.661 30 25 0.419 45 10 0.720 18 37 0.491
Cardiac insufficiency 8 38 4 0.068 30 20 0.950 42 8 0.125 12 38 0.136
Albumin
< 35 g/l 16 19 1 0.001 29 7 0.000 26 10 0.009 20 16 0.000
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Table 2 Associations among characteristics, BMI, REE, REE/kg and FBG (Continued)
35–40 g/ 38 78 16 68 64 99 33 55 77
> 40 g/l 27 89 22 57 81 120 18 33 105
Lymphocyte
< 1.1*109 13 26 3 0.092 23 19 0.031 34 8 0.305 15 27 0.401
1.1–3.2 64 133 32 121 108 179 50 84 145
> 3.2 4 27 4 10 25 32 3 9 26
NLR
< 5 73 179 37 0.135 144 145 0.473 233 56 0.316 101 188 0.603
≥ 5 8 7 2 10 7 12 5 7 10
Weight lost
No/Little 45 125 33 0.001 103 100 0.731 171 32 0.006 66 137 0.543
Middle 14 33 3 21 29 38 12 25 25
Large 22 28 3 30 23 36 17 17 36
FBG
Low 37 64 7 0.003 65 43 0.011 79 29 0.025
High 44 122 32 89 109 166 32
REE
Low 71 82 1 0.000 107 47 0.000
High 10 104 38 138 14
REE/kg
Low 32 174 39 0.000
High 49 12 0
CI confidence interval, OR odds ratio
The results were in bold, if the 95 % CI excluded 1 or p<0.05
Fig. 1 Survival curves of BMI classes
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whereas BMI and REE did not significantly affect the
OS. However, for non-metastatic esophageal cancers,
BMI and REE were important risk factors and proved to
be independent prognostic indicators.
Total lymphocyte counts, NLR and serum albumin
were recognized as nutrition based or inflammation-
based prognostic factors. Among the cancer patients,
those with digestive tract malignancies were more likely
to suffer from hypoalbuminaemia, which has been attrib-
uted to increased catabolism, obstruction of the digestive
tract and the systemic inflammatory response [12]. The
combined use of albumin and serum C-reactive protein
Fig. 2 Survival curves of albumin classes
Fig. 3 Survival curves of REE/kg classes
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were introduced by the Glasgow prognostic score [13,
14] and the combined use of albumin and lymphocyte
counts have been mentioned by the Onodera’s prognos-
tic nutritional index [15]. Hypoalbuminaemia has been
shown to correlate with ideal body weight, weight loss,
body cell mass and poor prognostic in cancer patients
[16]. In our cohort, hypoalbuminaemia associated with
weight loss, low REE and low FBG. Patients with serum
albumin levels <35 g/l had the 5-year survival rate of
26.7 %, compared to 57.8 % in patients with serum albu-
min > 40 g/l. Serum albumin was proved to be an inde-
pendent significant prognostic factor by multivariate
analysis even after adjusting for potential confounding
factors. To assess the impact of albumin on different
tumor stages, we divided patients into subgroups by N-
stage (N0 vs. N1-4), and found hypoalbuminaemia as
a worse survival factor in both N0 group (X2 = 11.078,
p = 0.004) and N1-4 group (X2 = 7.236, p = 0.027). But
the multivariate prognostic analysis for subgroups of
N0 and N1-4 exhibited that serum albumin as a
weaker prognostic value than other potential prognos-
tic factors. It may be explained by the different
clinical characteristics of each subgroup which may
impact on the prognostic value.
Fig. 4 Survival curves of FBG classes
Table 3 Multivariate prognostic analysis
Factors All patients N0 patients N1-4 patients
P OR 95 % CI P OR 95 % CI P OR 95 % CI
Age 0.001 1.844 1.279–2.661 0.286 1.417 0.747–2.689 0.005 1.982 1.228–3.200
Sex 0.229 0.757 0.481–1.191 0.016 0.309 0.119–0.803 0.465 0.818 0.478–1.401
Differentiation 0.004 1.560 1.154–2.107 0.761 0.921 0.542–1.564 0.002 1.885 1.267–2.805
T stage 0.005 1.463 1.125–1.903 0.024 1.611 1.065–2.436 0.018 1.528 1.076–2.168
N stage 0.000 1.610 1.366–1.898 - - - 0.056 1.317 0.992–1.749
BMI 0.755 0.945 0.660–1.351 0.035 0.540 0.304–0.959 0.789 0.939 0.594–1.485
REE 0.660 1.101 0.718–1.688 0.041 0.457 0.216–0.967 0.163 1.493 0.851–2.619
REE/kg 0.540 1.164 0.717–1.890 0.060 2.054 0.971–4.343 0.739 0.905 0.503–1.628
FBG 0.042 0.695 0.489–0.987 0.632 0.863 0.474–1.574 0.043 0.627 0.399–0.985
Albumin 0.030 0.757 0.589–0.973 0.863 0.960 0.605–1.524 0.198 0.819 0.604–1.110
CI confidence interval, OR odds ratio
The results were in bold, if the 95 % CI excluded 1 or p<0.05
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As a particular nonspecific marker of systemic inflam-
mation, an elevated NLR is hypothesized to be associ-
ated with poor survival in various solid tumors [17]. But
for esophageal cancer, its effect on long-term outcome is
still controversial [18, 19]. Most of previous studies did
not find the positive predictive values of NLR in patients
with esophageal cancer [20, 21]. In this study, there was
no significant difference in survival as the NLR cutoff
value taken as five because many previous literatures re-
ported optimal cutoff value as five [22]. We also did not
find the prognostic value of total lymphocyte counts in
patients with esophageal cancer.
A few studies focused on the influence of BMI on
postoperative outcomes in patients with EC and had
shown contradictory results, varying from no differences
in postoperative complications and mortality to a higher
incidence of individual complications (such as respira-
tory complications and anastomotic leak) in high BMI
patients [5–7]. In our study, we found no difference of
the frequency of postoperative complications and mor-
tality among different BMI patients. In addition, patients
with a high BMI had a higher frequency of diabetes.
Smoking patients appeared to have a lower BMI. Al-
though smoking is the preventable cause for esophageal
cancer, but it was not observed to be a poor prognostic
factor in our finding.
Previous studies had revealed contradictory results re-
garding the association between BMI and long-term out-
come in esophageal cancer patients [4–7, 23–25]. Most
of these studies were conducted in western populations
that have a high incidence rate of EAC, which occurs
more frequently in patients with a high BMI. But the
main type in Chinese populations is ESCC (67.9 % in
our data). The population is prone to be lean (26.5 %
with BMI < 20 and only 12.7 % with BMI > 25 in our
data) compared to Western populations. Based on our
data, compared with normal patients, we found a signifi-
cantly worse OS in low BMI patients and a significantly
better OS in high BMI patients on a univariate analysis.
The prognostic effect of BMI seems to be more valuable
on lymph node-negative patients than lymph node-
positive patients and proved to be independent prognos-
tic indicators.
High blood glucose level makes patients more suscep-
tible to certain postoperative complications such as sur-
gical site infections, sepsis, myocardial ischemia and so
on [26]. But no similar studies were reported concerning
esophageal cancer. Based on our date, FBG did not affect
the risk of all-cause mortality and postoperative
complications. Our study found low FBG level and
hypoalbuminaemia are inter-related. In the class of
albumin <35 g/l, only 44.4 % (16/36) patients had the
FBG > 90 mg/dL, but in the class of albumin >40 g/l, al-
most 76.1 % (105/138) patients had the FBG > 90 mg/dL,
and both hypoalbuminaemia and low FBG level were
proved to be worse survival factors. It is easy to measure
and monitor FBG or serum albumin in clinical research,
so both FBG and serum albumin can easily be used for
survival prognosis, and researchers can choose the
appropriate method according to their laboratory
conditions. To assess the impact of FBG on prognosis in
patients with esophageal cancer, both the univariate and
multivariate analysis proved that low FBG level
(≤90 mg/dL) was independently associated with poor
OS. These finding is consistent with previous studies
which suggested that hyperglycemia related microves-
sel changes may have a protective effect against neo-
plastic cell spread and metastasis in patients with
malignant tumors such as non-small cell lung cancer
and so on [27, 28].
REE is believed to be elevated in several types of tu-
mors, It has been hypothesized that increased energy ex-
penditure may contribute to the development of
malnutrition and weight loss [29]. Our study found pa-
tients with a low REE had significantly worse survival
compared with high REE (5-year survival rate: 40.4 % vs
55.3 %, p = 0.010). In addition, there was no significant
association of REE with postoperative complications and
mortality. To our knowledge, it is the first demonstration
of the prognostic value of estimated REE in postoperative
patients with EC. Our study also observed a significant
linear correlation between BMI and REE (p < 0.001),
showing that patients with low BMI tended to have low
REE. As the estimated REE largely depends on patients’
weight and height, the worse prognosis for low REE pa-
tients may reflect that these patients are under-nourished
and are likely to have poor prognosis as a result. In
addition, patients with low REE tended to be associated
with advanced T-stages, so we concluded that the ad-
vanced tumor stages may be another reason to explain the
low REE patients’ worse survival.
We also explore the relationship between REE and
REE/kg. We found the effect of REE on patient sur-
vival was opposite to that of REE/kg. Low REE as
well as high REE/kg was found to be a potential
worse prognostic indicator. The existing hypothesis
of REE is, the sum of the metabolic activities of in-
ternal organs, muscle, bone, and adipose tissue and
can reflect patient’s physiques and muscle volumes,
but REE/kg may reflect the diffusion, consumption
and metabolic rate of muscle. So patients with high
REE/kg have been found to lose more weight, have
lower BMI and have a worse survival, this finding is
consistent with the hypothesis.
In this research, low FBG was significantly associated
with low BMI, albumin and REE, a potential explanation
might be proposed. Individuals with esophageal cancer
commonly experience metabolic abnormalities. The
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abnormal state of insulin (hyperinsulinemia or insulin
resistance) is one cause, and it promotes cancer growth
and progression through its effects on the insulin and
insulin-like growth factor pathways [30]. Meanwhile,
diabetic microangiopathy render the vascular basal
membrane less digestible by tumor cells, which may play
a role in impeding neoplastic cell spread and metastasis.
Following are the main limitations in our study. First,
this is a retrospective study and the sample size is not
large. Second, all-cause mortality is used instead of
disease-specific deaths, the latter is difficult to confirm.
Third, we only chose R0 patients, so our results may not
be suitable for all patients.
Conclusion
In conclusion, it is the first article to explore the prog-
nostic significance of BMI, REE and FBG among patients
with EC. FBG level ≤90 mg/dL was independently asso-
ciated with poor survival for all patients. BMI and REE
were important prognostic factors and the value was sig-
nificant on lymph node negative patients. Therefore it is
advisable that the combined assessment of BMI, REE
and FBG can be used for a better preoperative assess-
ment and prognostic evaluation in esophageal cancer
patients.
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